The thiazolidinedione, compound 1, has previously shown pan-inhibition of the phosphoinositide 3-kinase (PI3K) class I isoforms. We hypothesized the derivatization of the thiazolidinedione core of compound 1 could introduce isoform selectivity. We report the synthesis, characterization, and inhibitory activity of a novel series of 4-iminothiazolidin-2-ones for inhibition of the class I PI3K isoforms. Their synthesis was successfully achieved by multiple pathways described in this paper. Initial in vitro data of 28 analogues demonstrated poor inhibition of all class I PI3K isoforms. However, we identified an alternate target, the phosphodiesterases, and present preliminary screening results showing improved inhibitory activity.
噻唑烷二酮化合物 1 以前曾显示出对磷酸肌酸 3-激酶(PI3K)I 类同工酶的泛抑制作用。我们假设化合物 1 的噻唑烷二酮核心的衍生化可以带来同工酶的选择性。我们报告了一系列新型 4-亚氨基噻唑烷-2-酮的合成、表征和抑制 I 类 PI3K 同工酶的活性。本文描述的多种途径成功实现了这些化合物的合成。28 种类似物的初步体外数据显示,它们对所有 I 类 PI3K 同工酶的抑制效果都很差。不过,我们发现了另一个靶点--磷酸二酯酶,并提出了初步筛选结果,显示其抑制活性有所提高。